Get the Stockscreener App
17.92
10.41%
1.69
After Hours:
17.80
-0.12
-0.67%
Alumis Inc stock is traded at $17.92, with a volume of 9.34M.
It is up +10.41% in the last 24 hours and up +61.15% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
See More
Previous Close:
$16.23
Open:
$17.39
24h Volume:
9.34M
Relative Volume:
4.44
Market Cap:
$1.87B
Revenue:
-
Net Income/Loss:
$-238.77M
P/E Ratio:
-0.6685
EPS:
-26.808
Net Cash Flow:
$-216.62M
1W Performance:
+83.61%
1M Performance:
+61.15%
6M Performance:
+441.39%
1Y Performance:
+122.61%
1-Day Range:
$16.70
$18.57
1-Week Range:
$7.85
$22.30
52-Week Range:
$2.7601
$22.30
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
17.92 | 1.69B | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Resumed | Guggenheim | Buy |
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
Should You Chase the Rally in Alumis Stock Today? - Barchart.com
Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise (ALMS) - Seeking Alpha
Biopharma firm Alumis extends gains after commencing $175 mln stock offering - TradingView — Track All Markets
Alumis Stock Hits Record High As Wall Street Cheers Phase 3 Psoriasis ‘Win’ — Analysts See Best-In-Class Potential - Stocktwits
Guggenheim raises Alumis stock price target to $32 on positive trial data - Investing.com UK
Why Alumis Stock Spiked Almost 100% Yesterday - TIKR.com
Alumis stock hits record high as Wall Street cheers phase 3 psoriasis 'win' — analysts see best-in-class potential - MSN
Should You Jump Into the Alumis Stock Rally Now? - Bitget
Alumis (ALMS) Sees Analyst Rating Boost with New Price Target | - GuruFocus
Sandisk, Alumis, Micron Technology, Ventyx Biosciences, And Western Digital: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Alumis Inc. (ALMS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Assessing Alumis (ALMS) Valuation After Positive Envudeucitinib Phase 3 Trial Success - simplywall.st
Alumis plans $175 million common stock offering By Investing.com - Investing.com Nigeria
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - Yahoo Finance
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - The Motley Fool
Alumis’ TYK2 envu in view as standout in psoriasis phase III - BioWorld MedTech
Alumis stock nearly doubles on 'truly remarkable' drug trial, plan to seek FDA approval - The Business Journals
Alumis Looks To Come From Behind In TYK2 Race - Citeline News & Insights
Why This J&J Rival Just Catapulted More Than 95% - Investor's Business Daily
Alumis Announces Proposed Public Offering of Common Stock - The Manila Times
Biotech Alumis plans $175M stock sale in new public offering - Stock Titan
Alumis (ALMS) Sees Analyst Rating Boost with New Price Target | ALMS Stock News - GuruFocus
Alumis Inc.: Is It Too Late To Buy? - StocksToTrade
Oppenheimer raises Alumis stock price target to $50 on positive trial results - Investing.com UK
Dow Jumps Over 400 Points; US Services Activity Falls In December - Benzinga
Alumis posts late-stage trial successes for TYK2 inhibitor in plaque psoriasis - FirstWord
Alumis Inc. Stock (ALMS) Opinions on Phase 3 Trial Results - Quiver Quantitative
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Alumis soars as TYK2 drug hits mark in psoriasis trials - BioPharma Dive
Alumis (NASDAQ:ALMS) Sets New 12-Month HighWhat's Next? - MarketBeat
Alumis Skin Medication Demonstrates Significant Advantages in Advanced Trials, Shares Surge - Bitget
Alumis’ TYK2 drug succeeds in key psoriasis studies, will seek FDA approval - Endpoints News
Alumis Shares Jump as Envudeucitinib Hits Phase III Endpoints in Psoriasis, NDA Planned for 2026 - MarketBeat
Baird raises Alumis stock price target to $35 on strong psoriasis trial data - Investing.com Canada
Alumis Stock Hits Record High on Psoriasis Drug Trial Results - Schaeffer's Investment Research
Alumis price target raised to $39 from $17 at Wells Fargo - TipRanks
Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars - Benzinga
Alumis (ALMS) Stock: Clinical Trial Results Send Shares Up 60% on Tuesday - Blockonomi
Alumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week high - TechStock²
Alumis surges on late-stage trial win for lead drug in plaque psoriasis - Seeking Alpha
Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Moving Higher On Tuesday - Benzinga
Why is ALMS stock rising today? - MSN
US Stocks Mixed; Nasdaq Gains Over 50 Points - Benzinga
Crypto: Alumis Inc. Explodes 113.96% – The Hidden Forces Behind This Stunning Rally! - InteractiveCrypto
Why Is ALMS Stock Rising Today? - Stocktwits
Crypto: Alumis Inc's Explosive 113.96% Surge: The Secrets Behind the Stunning Rally - InteractiveCrypto
Alumis Shares Surge After Plaque Psoriasis Drug Trials Meet Endpoints - MarketWatch
Alumis shares surge to record high as skin disease drug aces late-stage trials - MarketScreener
Alumis stock soars after drug shows strong psoriasis results in Phase 3 By Investing.com - Investing.com South Africa
Alumis stock soars after drug shows strong psoriasis results in Phase 3 - Investing.com Australia
Alumis unveils positive phase 3 data for psoriasis drug - MSN
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alumis Inc Stock (ALMS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director |
Dec 03 '25 |
Buy |
7.75 |
100,000 |
775,000 |
1,012,849 |
| AKKARAJU SRINIVAS | Director |
Dec 02 '25 |
Buy |
7.55 |
96,000 |
724,800 |
912,849 |
| AKKARAJU SRINIVAS | Director |
Dec 04 '25 |
Buy |
8.18 |
66,027 |
540,101 |
1,078,876 |
| AKKARAJU SRINIVAS | Director |
Dec 01 '25 |
Buy |
7.46 |
86,350 |
644,171 |
816,849 |
| AKKARAJU SRINIVAS | Director |
Nov 26 '25 |
Buy |
7.64 |
48,537 |
370,823 |
691,797 |
| AKKARAJU SRINIVAS | Director |
Nov 28 '25 |
Buy |
7.64 |
38,702 |
295,683 |
730,499 |
| Foresite Capital Management VI | 10% Owner |
Nov 21 '25 |
Buy |
7.38 |
72,212 |
532,925 |
2,614,215 |
| Tananbaum James B. | Director |
Nov 21 '25 |
Buy |
7.38 |
72,212 |
532,925 |
2,614,215 |
| Foresite Labs, LLC | 10% Owner |
Nov 21 '25 |
Buy |
7.38 |
72,212 |
532,925 |
2,614,215 |
| AKKARAJU SRINIVAS | Director |
Nov 20 '25 |
Buy |
7.20 |
125,743 |
905,350 |
643,260 |
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):